Holen Sie sich die Stockscreener-App
5.23
1.51%
-0.07
Schlusskurs vom Vortag:
$5.30
Offen:
$5.25
24-Stunden-Volumen:
70,191
Relative Volume:
0.15
Marktkapitalisierung:
$417.37M
Einnahmen:
$16.72M
Nettoeinkommen (Verlust:
$-77.80M
KGV:
-4.9466
EPS:
-1.0573
Netto-Cashflow:
$-43.78M
1W Leistung:
-3.87%
1M Leistung:
+6.53%
6M Leistung:
+68.93%
1J Leistung:
+338.66%
1-Tages-Spanne:
$5.19
$5.34
1-Wochen-Bereich:
$5.11
$5.62
52-Wochen-Spanne:
$0.9807
$6.83
Prelude Therapeutics Inc Stock (PRLD) Company Profile
Firmenname
Prelude Therapeutics Inc
Sektor
Branche
Telefon
(302) 467-1280
Adresse
175 INNOVATION BOULEVARD, WILMINGTON
Compare PRLD vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRLD
Prelude Therapeutics Inc
|
5.23 | 422.96M | 16.72M | -77.80M | -43.78M | -1.0573 |
VRTX
Vertex Pharmaceuticals Inc
|
522.83 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
800.17 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,000.20 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.32 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.18 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-19 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-06-20 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2024-03-13 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-02-20 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-12-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2022-11-21 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-09-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-07-29 | Eingeleitet | Jefferies | Buy |
| 2022-03-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-02-28 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-10-08 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-07-27 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-04-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-03-09 | Eingeleitet | Barclays | Overweight |
| 2020-11-20 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-10-20 | Eingeleitet | BofA Securities | Buy |
| 2020-10-20 | Eingeleitet | Goldman | Neutral |
| 2020-10-20 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Prelude Therapeutics Inc Aktie (PRLD) Neueste Nachrichten
Neuraptive Therapeutics, Inc. Announces Key Org… | UNI India - uniindia.com
Prelude Therapeutics (NASDAQ:PRLD) Reaches New 1-Year HighStill a Buy? - MarketBeat
Prelude Therapeutics (NASDAQ:PRLD) Shares Up 9.3%Time to Buy? - MarketBeat
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Prelude Therapeutics Hits New 52-Week High of $5.91, Reflecting Strong Growth - MarketsMojo
Prelude Therapeutics Incorporated reports results for the quarter ended June 30Earnings Summary - TradingView
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
We're Not Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn - Moomoo
Prelude Therapeutics (PRLD) Stock Rallies As Losses Ease But Milestones Remain Unclear - webull.com
Prelude Therapeutics (NASDAQ:PRLD) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
Prelude Therapeutics Reports Q2 2026 Earnings Featuring First Revenue and Reduced Losses - Kalkine Media
Prelude Therapeutics Reports $13.9 Million Q2 Net Loss - Quiver Quantitative
Prelude Therapeutics reports Q2 2026 results: $5.7M revenue, $13.9M net loss, $155.2M cash - TradingView
Prelude Therapeutics reports Q2 EPS (14c), consensus (19c) - TipRanks
Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Prelude Therapeutics Q2 revenue beats analyst expectations, net loss narrows - TradingView
Prelude Therapeutics 2Q Loss/Shr 14c >PRLD - Moomoo
Prelude Therapeutics (PRLD) Expected to Post Earnings on Thursday - MarketBeat
Pathos AI pads pipeline with $2.2B Alphamab deal, AZ pact - Fierce Biotech
Wall Street Analysts See a 58.42% Upside in Prelude Therapeutics (PRLD): Can the Stock Really Move This High? - Yahoo Finance
PRLD Q1 2026 Earnings: Narrower-than-Expected Loss Drives Stock RallyInvestor Earnings Call - vinanet.vn
Prelude Therapeutics (NASDAQ:PRLD) Earns Buy Rating from HC Wainwright - MarketBeat
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Sherwin-Williams Posts Upbeat Q2 Earnings, Joins Itron, Armstrong World And Other Big Stocks Moving Highe - Benzinga
PRLD|Prelude Therapeutics Inc|Price:4.640| - TradingKey
Prelude Therapeutics Inc (PRLD) Shareholder Structure: Major Shareholders & Institutional Holdings - tradingkey.com
PRLD|Prelude Therapeutics Inc|Price:3.830|Chg%:-0.100 - TradingKey
Prelude Therapeutics Inc (PRLD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Prelude Therapeutics (NASDAQ:PRLD) Upgraded to "Buy" at Wall Street Zen - MarketBeat
Prelude Therapeutics Incorporated Revenue Breakdown – NASDAQ:PRLD - tradingview.com
Prelude Therapeutics Inc (PRLD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Prelude Therapeutics stock trades around recent lows as clinical pipeline spending weighs on results - Ad-hoc-news.de
PRLD Q1 2026 Earnings: Narrower-than-Expected Loss Lifts SharesGross Profit Margin - vinanet.vn
Enterprise value to EBITDA forward of Prelude Therapeutics Incorporated – NASDAQ:PRLD - TradingView
Enterprise value to revenue forward of Prelude Therapeutics Incorporated – NASDAQ:PRLD - TradingView
Prelude Therapeutics Q1 2026 Earnings: EPS Surprises to the Upside but Stock Slips on Pipeline Uncertainty - dars.gov.et
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Prelude Therapeutics (PRLD) Upgraded to Buy: Here's Why - Yahoo Finance
H.C. Wainwright reiterates Prelude Therapeutics stock rating at buy By Investing.com - Investing.com Canada
JAK2 inhibitors reported in Prelude Therapeutics patent - BioWorld News
Prelude Therapeutics Hits New 52-Week High of $5.67, Up 527.79% - MarketsMojo
Citizens reiterates Prelude Therapeutics stock rating on IND filing By Investing.com - Investing.com Canada
Prelude Therapeutics Incorporated(NasdaqGS:PRLD) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Prelude Therapeutics Incorporated(NasdaqGS:PRLD) added to Russell 2500 Growth Benchmark - marketscreener.com
Prelude Therapeutics Incorporated(NasdaqGS: PRLD) added to Russell 2000 Index - marketscreener.com
Prelude Therapeutics Incorporated(NasdaqGS:PRLD) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Prelude Therapeutics Incorporated(NasdaqGS:PRLD) added to Russell 2000 Growth Benchmark - marketscreener.com
Prelude Therapeutics Incorporated(NasdaqGS:PRLD) added to Russell 3000E Growth Benchmark - marketscreener.com
Prelude Therapeutics Incorporated(NasdaqGS: PRLD) added to Russell Microcap Index - marketscreener.com
Prelude Therapeutics Incorporated(NasdaqGS: PRLD) added to Russell 3000E Index - marketscreener.com
MapLight Therapeutics appoints two directors to board - Investing.com UK
Finanzdaten der Prelude Therapeutics Inc-Aktie (PRLD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.72%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):